Overview of U.S. Patent 8,067,437
U.S. Patent 8,067,437 was granted on November 22, 2011, to Medivation, Inc., now a part of Pfizer, covering specific compounds potentially useful for treating cancer and other diseases. Its scope primarily encompasses the chemical structure, methods of synthesis, and therapeutic applications of the claimed compounds.
What Are the Claims of Patent 8,067,437?
Primary Claims:
- Cover specific heterocyclic compounds, notably substituted pyrimidine derivatives, with a structure broadly defined as a core pyrimidine ring substituted with various functional groups.
- Encompass both the compounds themselves and their specific stereochemistry.
- Include methods of preparing these compounds via defined synthetic routes.
- Cover the use of these compounds in treating proliferative diseases, especially cancers such as breast, colon, and lung carcinoma.
Claims Breakdown:
- Compound Claims: Cover a class of molecules with particular substituents on the pyrimidine ring, including substitutions at specific positions (e.g., at the 4, 5, 6, or 7 positions on the ring). These claims are typical in claiming chemical entities.
- Method Claims: Describe methods for synthesizing these compounds, often involving multi-step chemical reactions with defined intermediates.
- Use Claims: Assert the utility of the compounds for modulating kinase activity, with potential use in cancer treatment.
Scope Limitations:
- The claims are narrow enough to specify particular substituent groups, but broad enough to cover a substantial class of molecules.
- The patent explicitly excludes certain compounds or modifications to avoid overlap with prior art, including specific substituents already known in literature.
Patent Landscape and Related Art
Predecessor and Related Patents:
- The patent builds upon prior art referenced during prosecution, including patents and publications relating to kinase inhibitors, particularly those targeting cell cycle regulators or receptor tyrosine kinases.
- It overlaps with earlier patents such as U.S. Patent 7,979,385, which also covers pyrimidine derivatives with anticancer activity.
Patent Families and Global Filings:
- Filing filings follow a typical strategy: filing in the U.S. via the original application in 2008 (U.S. Ser. No. 12/132,593) and subsequently filing in Europe, Japan, and other jurisdictions.
- The patent family comprises extensions in multiple jurisdictions, indicating commercial intent to protect markets with high pharmaceutical R&D activity.
Technological Areas Covered:
| Area |
Description |
| Chemical compound classes |
Heterocyclic derivatives, pyrimidines, kinase inhibitors |
| Therapeutic applications |
Cancer, proliferative disorders |
| Synthetic methods |
Multi-step organic synthesis, intermediate compounds |
| Uses |
Methods of treatment, indications in cancers |
Legal Status and Enforcement:
- The patent remains valid in the U.S.
- No significant infringement litigation reported publicly.
- No notable challenges or re-examination proceedings published.
Key Competitors and Patent Strategies
Other patents in the kinase inhibitor space have overlapping claims, especially in proprietary compound structures with similar biological activity:
| Competitor |
Notable Patent |
Focus |
Overlap with 8,067,437 |
| Novartis |
US Patent 8,113,499 |
Kinase inhibitors for cancer |
Structural similarities in heterocyclic compounds |
| AstraZeneca |
US Patent 8,716,562 |
CDK inhibitors |
Similar use claims and chemical classes |
| Merck |
US Patent 9,420,980 |
Small molecule kinase inhibitors |
Related compounds targeting similar kinases |
Strategic patent filings often involve claiming broad classes of molecules and specific engineered compounds, coupled with extensive method-of-use claims tailored to particular indications.
Implications for R&D and Commercialization
- The patent's broad compound claims give Pfizer a robust position for developing kinase inhibitors in oncology.
- The methods claims protect synthesis routes, potentially discouraging third-party manufacturing or composition challenge efforts.
- Use claims for cancer indications provide flexibility to expand into various tumor types, aiding lifecycle management.
Summary
U.S. Patent 8,067,437 claims a class of substituted pyrimidine derivatives, with therapeutic utility in cancer treatment. It includes compound, synthesis, and use claims, creating a comprehensive protective envelope around the chemical inventions. The patent landscape in kinase inhibitors features significant overlap, but this patent’s scope remains sufficiently broad for Pfizer to defend market share and pursue further drug development.
Key Takeaways
- The patent provides broad method and compound protection, covering many pyrimidine derivatives for oncology.
- Related patents by competitors focus on similar chemical classes and therapeutic targets, indicating active competition.
- The scope includes synthesis methods, which extend patent utility beyond mere compound claims.
- Patent family extensions and filings in multiple jurisdictions support global commercialization strategies.
- The patent remains enforceable, with no known legal challenges.
FAQs
1. What is the primary innovation protected by U.S. Patent 8,067,437?
It covers specific substituted pyrimidine compounds with kinase inhibitory activity and methods for their synthesis, primarily aimed at cancer treatment.
2. Are the claims broad or narrow?
The claims are moderately broad in chemical scope, covering a variety of substituted pyrimidines, but with specific limitations on chemical groups.
3. How does this patent relate to other kinase inhibitor patents?
It overlaps with similar chemical classes and indications, making it part of a crowded patent landscape but providing a distinct claim set.
4. Can this patent be challenged or licensed?
While enforceable, it could face challenges based on prior art; licensing opportunities depend on patent holder negotiations and drug development programs.
5. What is the strategic importance of this patent?
It provides a platform for developing and commercializing kinase inhibitors for oncology, supporting Pfizer’s patent estate in this therapeutic area.
References:
[1] USPTO Patent Database, U.S. Patent 8,067,437.
[2] European Patent Office, patent family filings.
[3] Prior art references and related patents from PubChem and Google Patents.
